Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome
The Medical Letter on Drugs and Therapeutics · 13.04.2026 · 68 (1752) · 68-62
DOI: 10.58347/tml.2026.1752c ↗Kurz gefasst
Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 13.04.2026. Die Arbeit wurde bisher 1-mal zitiert (Crossref).
Abstract (Originalsprache)
Plozasiran (Redemplo – Arrowhead), an apolipoprotein C-III (apoC-III)-directed small interfering ribonucleic acid (siRNA), has been approved by the FDA to reduce triglyceride levels in adults with familial chylomicronemia syndrome (FCS). It is the second drug to be approved in the US for this indication; the apoC-III-directed antisense oligonucleotide olezarsen (Tryngolza) was approved in 2024.
Schlagwörter
Stichwörter der Autor:innen
Zitieren
APA
(2026). Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome. The Medical Letter on Drugs and Therapeutics, 68(1752), 68-62. https://doi.org/10.58347/tml.2026.1752c
Vancouver
Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome. The Medical Letter on Drugs and Therapeutics. 2026;68(1752):68-62. doi:10.58347/tml.2026.1752c
BibTeX
@article{euvimed2026,
title = {Plozasiran (Redemplo) for Familial Chylomicronemia Syndrome},
journal = {The Medical Letter on Drugs and Therapeutics},
year = {2026},
volume = {68},
number = {1752},
pages = {68--62},
doi = {10.58347/tml.2026.1752c}
}
EUVIMED